JNJorge Willian Leandro Nascimento

Jorge Willian Leandro Nascimento

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jorge Willian Leandro Nascimento has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of acute, subacute, and chronic exercise on plasma s-Klotho levels: a systematic review and meta-analysis

    by Túlio Medina Dutra de Oliveira, Diogo Carvalho Felício, Taynara da Silva Ribeiro, José Elias Filho, Francisco José Amaro-Gahete, Giovani Bernardo Costa, Jorge Willian Leandro Nascimento, Maycon de Moura Reboredo, Carla Malaguti

    Exercise exerts beneficial effects on multiple physiological systems, influencing biomarkers associated with aging processes and chronic diseases. This systematic review and meta-analysis aimed to evaluate the acute, subacute, and chronic effects of exercise on s-Klotho levels in healthy individuals and patients with chronic diseases. A comprehensive search was conducted in electronic databases. Included studies were randomized and non-randomized studies assessing the effects of aerobic, resistance, or combined exercise on s-Klotho levels. Interventions were classified as acute (single session), subacute (< 12 weeks), or chronic (≥ 12 weeks). Risk of bias was assessed using RoB 2 and ROBINS-I tools, and quality of evidence was evaluated with the GRADE framework. Forty-one studies were included in the qualitative synthesis, and 30 in the meta-analysis, comprising 2,765 participants (18–85 years). Twenty-five involved healthy individuals, while 21 included patients with chronic diseases. Acute and subacute aerobic exercise increased s-Klotho levels in healthy individuals (SMD 0.69; 95%CI 0.41–0.97) and diseased populations (SMD 0.62; 95%CI 0.11–1.12). Chronic exercise (12–36 weeks) showed significant increases in healthy (SMD 0.57; 95%CI 0.33–0.82) and diseased populations (SMD 1.51; 95%CI 0.87–2.16). Resistance exercise thrice weekly demonstrated the highest effect (SMD 1.60; 95%CI 0.81–2.38). Most studies had high risk of bias, with quality of evidence ranging from very low to moderate. Exercise significantly increases s-Klotho levels, with acute and subacute aerobic sessions benefiting healthy and diseased populations, while chronic resistance exercise elicited greater responses in diseased populations. Despite promising findings, low methodological quality suggests cautious interpretation.

  • Open Access

    Attenuation of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice by Licochalcone A

    by Lívia Beatriz Almeida Fontes, Ludmila de Souza Caputo, Débora dos Santos Dias, Chislene Pereira Vanelli, Igor Rosa Meurer, Jorge Willian Leandro Nascimento, Aline Corrêa Ribeiro, Beatriz Julião Vieira Aarestrup, Fernando Monteiro Aarestrup, Ademar Alves da Silva Filho, et al.

    Multiple sclerosis (MS) is an autoimmune inflammatory and demyelinating disease of the central nervous system (CNS) that affects more than 2.5 million people worldwide. The experimental autoimmune encephalomyelitis (EAE) is an appropriate and a well-establish model for studying the pathogenesis of MS. Licochalcone A (LicoA) is a chalcone obtained from the roots of Glycyrrhiza inflata (Fabaceae) that has in vitro immunomodulatory effects. EAE was induced in C57BL/6 mice with myelin oligodendrocyte glycoprotein and we have investigated the treatment of LicoA in this animal model. LicoA was isolated from G. inflata and was orally administered during the development of EAE. The capacity of absorption and distribution of LicoA, after gavage, to the brain was performed by HPLC. The clinical course and body weight were performed daily, cytokines (ELISA) and oxygen radicals production (NO and H2O2) were investigated. The CNS sections were stained by hematoxylin and eosin. After the treatment, by HPLC, at the first time, we analyzed the penetration between tissue/plasma, and our results showed that LicoA was present in serum and reached the mice brain with a good distribution. LicoA reduced clinical score and severity of EAE-mice, as well as inhibited H2O2, NO, TNF-α, IFN-γ and, mainly, IL-17 production. Histopathological analysis confirmed that LicoA treatment significantly reduced the numbers of inflammatory infiltrates and attenuates neurological damages in the CNS. These findings demonstrate that the oral treatment of LicoA significantly ameliorated the inflammatory signs associated with EAE, since it is effective at reducing both disease onset and severity.

  • Open Access

    The Role of Pharmacogenetics in the Therapeutic Response to Thiopurines in the Treatment of Inflammatory Bowel Disease: A Systematic Review

    by Aline C. Ribeiro, Pâmela S. A. S. Gerheim, Julio Maria Fonseca Chebli, Jorge Willian L. Nascimento, Priscila de Faria Pinto

    This study focuses on the use of thiopurines for treating inflammatory bowel diseases (IBD). These drugs undergo enzymatic changes within the body, resulting in active and inactive metabolites that influence their therapeutic effects. The research examines the role of genetic polymorphisms in the enzyme thiopurine S-methyltransferase (TPMT) in predicting the therapeutic response and adverse effects of thiopurine treatment. The TPMT genotype variations impact the individual responses to thiopurines. Patients with reduced TPMT activity are more susceptible to adverse reactions (AEs), such leukopenia, hepatotoxicity, pancreatitis, and nausea, which are common adverse effects of thiopurine therapy. The therapeutic monitoring of the metabolites 6-thioguanine nucleotides (6-TGN) and 6-methyl mercaptopurine (6-MMP) is proposed to optimize treatment and minimize AEs. Patients with higher 6-TGN levels tend to have better clinical responses, while elevated 6-MMP levels are linked to hepatotoxicity. Genotyping for TPMT before or during treatment initiation is suggested to tailor dosing strategies and enhance treatment efficacy while reducing the risk of myelosuppression. In conclusion, this study highlights the importance of considering genetic variations and metabolite levels in optimizing thiopurine therapy for IBD patients, focusing on balance therapeutic efficacy with the prevention of adverse effects and contributing to personalized treatment and better patient outcomes.


  • Open Access

    Identification of Asiaticoside from Centella erecta (Apiaceae) as Potential Apyrase Inhibitor by UF-UHPLC-MS and Its In Vivo Antischistosomal Activity

    by Lara Soares Aleixo de Carvalho, Vinícius Carius de Souza, Vinícius C. Rodrigues, Aline Correa Ribeiro, Jorge Willian Leandro Nascimento, Priscila V. S. Z. Capriles, Priscila de F. Pinto, Josué de Moraes, Ademar Alves da Silva Filho

    Schistosomiasis, caused by parasites of the genus Schistosoma, is a neglected disease with high global prevalence, affecting more than 240 million people in several countries. Praziquantel (PZQ) is the only drug currently available for the treatment. S. mansoni NTPDases (known as SmNTPDases, ATP diphosphohydrolases or ecto-apyrases) are potential drug targets for the discovery of new antischistosomal drugs. In this study, we screen NTPDases inhibitors from Centella erecta (Apiaceae) using an ultrafiltration combined UHPLC-QTOF-MS method and potato apyrase, identifying asiaticoside as one of the apyrase-binding compounds. After isolation of asiaticoside from C. erecta extract, we assessed its in vivo antischistosomal activities against Schistosoma mansoni worms and its in vitro enzymatic apyrase inhibition. Also, molecular docking analysis of asiaticoside against potato apyrase, S. mansoni NTPDases 1 and 2 were performed. Asiaticoside showed a significant in vitro apyrase inhibition and molecular docking studies corroborate with its possible actions in potato apyrase and S. mansoni NTPDases. In mice harboring a patent S. mansoni infection, a single oral dose of asiaticoside (400 mg/kg. p.o.) showed significantly in vivo antischistosomal efficacy, markedly decreasing the total worm load and egg burden, giving support for further exploration of apyrase inhibitors as antischistosomal agents.


  • Open Access

    Evaluation of copaiba oil as enhancer of ibuprofen skin permeation

    by Rodrigo José Lupatini Nogueira, Richard Michael Grazul, Ademar Alves Da Silva Filho, Jorge Willian Leandro Nascimento


  • Open Access

    POLÍTICA DE PROIBIÇÃO DA DIPIRONA

    by Flávia de Paula Gonçalves Guimarães, Ernane Cláudio Souza-Júnior, Carlos Alberto Mourão Júnior, Jorge Willian Leandro Nascimento

    A dipirona é um dos analgésicos/antipiréticos mais utilizados no Brasil. Entretanto, devido às suspeitas de causar agranulocitose, esse medicamento foi retirado do mercado de mais de 30 países, incluindo: Estados Unidos, Japão, Austrália, e grande parte da União Europeia. Nosso objetivo foi questionar a proibição do medicamento. Dessa forma, foi realizada uma revisão comentada da literatura acerca das possíveis reações adversas e toxicidade associadas ao uso da dipirona bem como a polêmica questão relacionada à sua proibição. Apesar de a dipirona estar historicamente associada à ocorrência de agranulocitose, diversos estudos mostraram que quando comparada com outros analgésicos/antipiréticos disponíveis no mercado, esse fármaco apresenta melhor relação risco-benefício, além de possuir toxicidade em níveis aceitáveis. Em contrapartida, sua ampla disponibilidade, boa margem de segurança e baixo custo constituem-se importantes justificativas para seu uso e comercialização como medicamento isento de prescrição. Este ensaio discute ainda aspectos éticos, sociológicos e políticos que perpassam a proibição da dipirona.


  • Open Access

    POLÍTICA DE PROIBIÇÃO DA DIPIRONA

    by Flávia de Paula Gonçalves Guimarães, Ernane Cláudio Souza-Júnior, Carlos Alberto Mourão Júnior, Jorge Willian Leandro Nascimento

    A dipirona é um dos analgésicos/antipiréticos mais utilizados no Brasil. Entretanto, devido às suspeitas de causar agranulocitose, esse medicamento foi retirado do mercado de mais de 30 países, incluindo: Estados Unidos, Japão, Austrália, e grande parte da União Europeia. Nosso objetivo foi questionar a proibição do medicamento. Dessa forma, foi realizada uma revisão comentada da literatura acerca das possíveis reações adversas e toxicidade associadas ao uso da dipirona bem como a polêmica questão relacionada à sua proibição. Apesar de a dipirona estar historicamente associada à ocorrência de agranulocitose, diversos estudos mostraram que quando comparada com outros analgésicos/antipiréticos disponíveis no mercado, esse fármaco apresenta melhor relação risco-benefício, além de possuir toxicidade em níveis aceitáveis. Em contrapartida, sua ampla disponibilidade, boa margem de segurança e baixo custo constituem-se importantes justificativas para seu uso e comercialização como medicamento isento de prescrição. Este ensaio discute ainda aspectos éticos, sociológicos e políticos que perpassam a proibição da dipirona.

  • Simultaneous Monitoring of Azathioprine Metabolites in Erythrocytes of Crohn’s Disease Patients by HPLC-UV

    by Aline Correa Ribeiro, Luciane Henriques Furtado Barroso, Carlos Alberto Mourao-Junior, Julio Maria Fonseca Chebli, Jorge Willian Leandro Nascimento

    The conversion of azathioprine (AZA) to active 6-thioguanine nucleotides (6-TGN) is essential for its clinical efficacy; however, another metabolite formed, 6-methylmercaptopurine (6-MMP), is related to hepatotoxicity. Blood samples were collected from 37 patients under AZA’s treatment, and a new HPLC-UV method was validated and applied for simultaneous quantification of 6-TGN and 6-MMP in erythrocytes of Crohn’s disease (CD) patients. The concentration of 6-TGN and 6-MMP found ranged from 4.5 to 2,456 ρmol/8 × 108 red blood cells (RBCs) for 6-TGN and from 170 to 53,951 ρmol/8 × 108 RBCs for 6-MMP. Reduced levels of 6-MMP in patients into combo therapy with AZA and allopurinol (2,031 ρmol/8 × 108 RBCs) have been observed when compared to patients undergoing monotherapy with AZA (9,098 ρmol/8 × 108 RBCs). Additionally, there was a negative correlation (r = −83.7%, P < 0.05) between lymphocyte count and 6-TGN levels. The method developed is reliable, accurate and reproducible and can be used as an important tool in the monitoring routine of patients with CD under AZA treatment, allowing the individualization of the dose, monitoring adherence to the treatment and the evaluation of the clinical outcome of these patients.


  • Improved Method for Obtaining of Arctigenin from Arctium Lappa L. and its Antiproliferative Effect on Human Hepatocarcinoma HepG2 Cells

    by Renan S. Teixeira, Paulo H.D. Carvalho, Jair A.K. Aguiar, Valquíria P. Medeiros, Ademar A. Da Silva Filho, Jorge W.L. Nascimento

    Background: Arctigenin is a lignan found in Arctium lappa L. (Asteraceae) that displays anti-inflammatory activities. Previous studies showed that the crude extract of A. Lappa has antitumor activity in human liver carcinoma, lung and stomach cancer cells. The aim of this study was to obtain arctigenin from A. lappa L., as well as to evaluate its antiproliferative effects in cells of liver carcinoma (HepG2) and fibroblasts (NIH/3T3). Methods: Arctigenin was obtained from the hydrolysis of arctiin, which was isolated from the crude extract of A. lappa. The effects of arctigenin and arctiin on HepG2 cell viability and cell adhesion were analyzed by MTT method. Adhesion assay was also carried out to evaluate the antitumor activity. Results: Our results showed that the analytical process to obtain arctigenin was fast and easy. In vitro experiments showed that arctigenin (107-269 μM) decreased HepG2 cells viability and did not cause cytotoxicity on NIH/3T3 cells. Arctigenin (27-269 μM) demonstrated anti-adhesion in HepG2 cells in a concentration-dependent manner, when compared with control. Conclusion: These results suggest a promising pharmacological activity for arctigenin as an antiproliferative compound.


  • Pharmacokinetic profile and oral bioavailability of Kaurenoic acid from Copaifera spp. in rats

    by Dalyara Mendonça de Matos, Milainy Rocha Viana, Marcela Cristina de Oliveira Alvim, Lara Soares Aleixo de Carvalho, Laura Hora Rios Leite, Ademar Alves Da Silva Filho, Jorge Willian Leandro Nascimento